These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6753478)

  • 1. Modified human immune serum globulin for intravenous administration: in vitro opsonic activity and in vivo protection against group B streptococcal disease in suckling rats.
    Fischer GW; Hunter KW; Wilson SR
    Acta Paediatr Scand; 1982 Jul; 71(4):639-44. PubMed ID: 6753478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci.
    Fischer GW; Wilson SR; Hunter KW
    J Clin Immunol; 1982 Apr; 2(2 Suppl):31S-35S. PubMed ID: 7045156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy of a modified immune serum globulin in experimental group B streptococcal infection.
    Santos JI; Shigeoka AO; Rote NS; Hill HR
    J Pediatr; 1981 Dec; 99(6):873-9. PubMed ID: 7031210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K1 infection.
    Bortolussi R; Fischer GW
    Pediatr Res; 1986 Feb; 20(2):175-8. PubMed ID: 3511443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyvalent group B streptococcal immune globulin for intravenous administration: overview.
    Fischer GW; Hemming VG; Gloser HP; Bachmayer H; von Pilar CE; Wilson SR; Baron PA
    Rev Infect Dis; 1990; 12 Suppl 4():S483-9; discussion S489-91. PubMed ID: 2194273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune globulin for intravenous use: enhancement of in vitro opsonophagocytic activity of neonatal serum.
    Givner LB; Edwards MS; Anderson DC; Baker CJ
    J Infect Dis; 1985 Feb; 151(2):217-20. PubMed ID: 3918123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats.
    Weisman LE; Lorenzetti PM
    J Pediatr; 1989 Sep; 115(3):445-50. PubMed ID: 2671331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opsonic antibody response of female rats to type III group B streptococcal immunization: a model for maternal immunity.
    Heiman HS; Weisman LE
    Vet Immunol Immunopathol; 1990 Jan; 24(1):79-89. PubMed ID: 2180204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.
    Givner LB
    Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.
    Weisman LE; Anthony BF; Hemming VG; Fischer GW
    J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplacental or enteral transfer of maternal immunization-induced antibody protects suckling rats from type III group B streptococcal infection.
    Heiman HS; Weisman LE
    Pediatr Res; 1989 Dec; 26(6):629-32. PubMed ID: 2689988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus.
    Kim KS; Wass CA; Kang JH; Anthony BF
    J Infect Dis; 1986 Jun; 153(6):1092-7. PubMed ID: 3517187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human IgG 3 is opsonic in vitro against type III group B streptococci.
    Kim JS; Kim KS; Wass CA; Short JA; Heiner DC
    J Clin Immunol; 1990 May; 10(3):154-9. PubMed ID: 2195055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.
    Hill HR; Kelsey DK; Gonzales LA; Raff HV
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S87-91. PubMed ID: 1728992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease.
    Givner LB; Baker CJ
    J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.
    Hill HR; Gonzales LA; Knappe WA; Fischer GW; Kelsey DK; Raff HV
    J Infect Dis; 1991 Apr; 163(4):792-8. PubMed ID: 2010632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review.
    Fischer GW; Weisman LE; Hemming VG
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S92-7. PubMed ID: 1728993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody.
    Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF
    Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models.
    Givner LB; Edwards MS; Baker CJ
    J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.